Cas:886500-26-1 2-Chloro-6-(trifluoromethyl)benzyl bromide manufacturer & supplier

We serve Chemical Name:2-Chloro-6-(trifluoromethyl)benzyl bromide CAS:886500-26-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-Chloro-6-(trifluoromethyl)benzyl bromide

Chemical Name:2-Chloro-6-(trifluoromethyl)benzyl bromide
CAS.NO:886500-26-1
Synonyms:18762173;α-Bromo-2-chloro-6-(trifluoromethyl)toluene;2-(Bromomethyl)-1-chloro-3-(trifluoromethyl)benzene;2-(Bromomethyl)-3-chlorobenzotrifluoride;2-Chloro-6-(trifluoromethyl)benzyl bromide;FXFFR CG B1E;Benzene, 2-(bromomethyl)-1-chloro-3-(trifluoromethyl)-
Molecular Formula:C8H5BrClF3
Molecular Weight:273.478
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:214.0±35.0 °C at 760 mmHg
Density:1.7±0.1 g/cm3
Index of Refraction:1.505
PSA:
Exact Mass:271.921509
LogP:4.28

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:III


Contact us for information like 18762173 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzene, 2-(bromomethyl)-1-chloro-3-(trifluoromethyl)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,18762173 Use and application,α-Bromo-2-chloro-6-(trifluoromethyl)toluene technical grade,usp/ep/jp grade.


Related News: McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. (S)-tert-Butyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolidine-1-carboxylate manufacturers About eight months after originally teaming up on neuromuscular diseases, Takeda and PeptiDream have expanded the pact to include several central nervous system targets, while revealing the tie-up could be worth more than $3.5 billion. (6-Phenoxypyridin-3-yl)boronic acid suppliers The study also found that the inhaled version of the vaccine did not cause serious side effects, demonstrating an encouraging safety profile in the early-stage trial. (13S,14S)-3-Methoxy-13,14-dimethyl-6,7,11,12,13,14,15,16-octahydro-cyclopenta[a]phenanthren-17-one vendor & factory.